Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MicroRNA-mRNA integral analysis in CD4+ T cell in primay biliary cholangitis (PBC)

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE93172 | GEO | 2017/01/06

SECONDARY ACCESSION(S): PRJNA360230

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

microRNA-mRNA integral analysis in CD4+ T cell in primay biliary cholangitis (PBC)

Project description:microRNA-mRNA integral analysis in CD4+ T cell in primay biliary cholangitis (PBC)

| PRJNA360230 | ENA

mRNA profile in CD4+ T cell in healthy control and Primay biliary cholangitis (PBC) [mRNA]

Project description:Primary biliary cholangitis (PBC), formally known as primary biliary cirrhosis, is an autoimmune liver disease of unknown pathogenesis. Consequently, therapeutic targets for PBC have yet to be identified. As CD4+ T cells play a pivotal role in immunological dysfunction observed in PBC, we analyzed microRNA(miRNA) and mRNA expression in CD4+ T cells to investigate PBC pathogenesis and identify novel therapeutic targets.

2017-01-06 | GSE93170 | GEO

microRNA profile in CD4+ T cell in healthy control and Primay biliary cholangitis (PBC) [miRNA]

2017-01-06 | GSE93171 | GEO

The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.

Project description:Primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) is an autoimmune liver disease in which a cycle of immune mediated biliary epithelial cell injury, cholestasis and progressive fibrosis can culminate over time in an end-stage biliary cirrhosis. Both genetic and environmental influences are presumed relevant to disease initiation. PBC is most prevalent in women and those over the age of 50, but a spectrum of disease is recognised in adult patients globally; male sex, younger age at onset (<45) and advanced disease at presentation are baseline predictors of poorer outcome. As the disease is increasingly diagnosed through the combination of cholestatic serum liver tests and the presence of antimitochondrial antibodies, most presenting patients are not cirrhotic and the term cholangitis is more accurate. Disease course is frequently accompanied by symptoms that can be burdensome for patients, and management of patients with PBC must address, in a life-long manner, both disease progression and symptom burden. Licensed therapies include ursodeoxycholic acid (UDCA) and obeticholic acid (OCA), alongside experimental new and re-purposed agents. Disease management focuses on initiation of UDCA for all patients and risk stratification based on baseline and on-treatment factors, including in particular the response to treatment. Those intolerant of treatment with UDCA or those with high-risk disease as evidenced by UDCA treatment failure (frequently reflected in trial and clinical practice as an alkaline phosphatase >1.67?× upper limit of normal and/or elevated bilirubin) should be considered for second-line therapy, of which OCA is the only currently licensed National Institute for Health and Care Excellence recommended agent. Follow-up of patients is life-long and must address treatment of the disease and management of associated symptoms.

| S-EPMC6109281 | biostudies-literature

mRNA and microRNA profile in colon cancer

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2014-01-01 | E-GEOD-29623 | biostudies-arrayexpress

Digital expression profiling highlights a distinct live RNA signature in high-risk Primary Biliary Cholangitis (PBC)

Project description:Using outcome after long term follow-up to define risk at disease presentation high risk (n=9 who went on to require liver transplantation) and low risk (n=7 who responded fully to UDCA) patients were identified and their first liver biopsies retrieved. RNA was successfully extracted and analysed using nanostringÂ® transcriptomics. Patients with progressive disease appear to have a distinct molecular signature. high risk (n=9 who went on to require liver transplantation) and low risk (n=7 who responded fully to UDCA) patient material was processed along with non-diseased control liver (n=8)

2016-04-02 | E-GEOD-79850 | biostudies-arrayexpress

microRNA and geneexpression profiles in organoids derived from biliary tract carcinomas

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-03-15 | GSE112408 | GEO

Digital expression profiling highlights a distinct live RNA signature in high-risk Primary Biliary Cholangitis (PBC)

Project description:Using outcome after long term follow-up to define risk at disease presentation high risk (n=9 who went on to require liver transplantation) and low risk (n=7 who responded fully to UDCA) patients were identified and their first liver biopsies retrieved. RNA was successfully extracted and analysed using nanostring® transcriptomics. Patients with progressive disease appear to have a distinct molecular signature.

2016-04-02 | GSE79850 | GEO

NPM1 mutation-modulated microRNA-mRNA regulation in acute myeloid leukemia

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2017-05-03 | E-GEOD-68469 | biostudies-arrayexpress

SUMO is an Integral and Instructive Component of Chromatin in Cell Growth and Senescence

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2013-07-24 | E-GEOD-42213 | biostudies-arrayexpress